Acid-Base Composition With Use of hemoDialysates

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

September 30, 2015

Conditions
End Stage Renal Disease
Interventions
DEVICE

Group 1: GranuFlo

Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.

DEVICE

Group 2: NaturaLyte

Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.

Trial Locations (1)

37920

Volunteer Research Group and New Orleans Center for Clinical Research, Knoxville

All Listed Sponsors
lead

Fresenius Medical Care North America

INDUSTRY

NCT02334267 - Acid-Base Composition With Use of hemoDialysates | Biotech Hunter | Biotech Hunter